BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36208791)

  • 1. Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer.
    Liu X; Deng J; Yuan Y; Chen W; Sun W; Wang Y; Huang H; Liang B; Ming T; Wen J; Huang B; Xing D
    Pharmacol Ther; 2022 Nov; 239():108296. PubMed ID: 36208791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Trop2 in solid tumors: a look into structures and novel epitopes.
    Liu X; Li J; Deng J; Zhao J; Zhao G; Zhang T; Jiang H; Liang B; Xing D; Wang J
    Front Immunol; 2023; 14():1332489. PubMed ID: 38179054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.
    Coates JT; Sun S; Leshchiner I; Thimmiah N; Martin EE; McLoughlin D; Danysh BP; Slowik K; Jacobs RA; Rhrissorrakrai K; Utro F; Levovitz C; Denault E; Walmsley CS; Kambadakone A; Stone JR; Isakoff SJ; Parida L; Juric D; Getz G; Bardia A; Ellisen LW
    Cancer Discov; 2021 Oct; 11(10):2436-2445. PubMed ID: 34404686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy.
    Son S; Shin S; Rao NV; Um W; Jeon J; Ko H; Deepagan VG; Kwon S; Lee JY; Park JH
    Int J Biol Macromol; 2018 Apr; 110():406-415. PubMed ID: 29055700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trop2 Expression in Extramammary Paget's Disease and Normal Skin.
    Ito T; Tanegashima K; Tanaka Y; Hashimoto H; Murata M; Oda Y; Kaku-Ito Y
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer.
    Cortesi M; Zanoni M; Maltoni R; Ravaioli S; Tumedei MM; Pirini F; Bravaccini S
    Expert Opin Ther Targets; 2022 Jul; 26(7):593-602. PubMed ID: 35962580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.
    Shen M; Liu S; Stoyanova T
    Am J Clin Exp Urol; 2021; 9(1):73-87. PubMed ID: 33816696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors.
    Dum D; Taherpour N; Menz A; Höflmayer D; Völkel C; Hinsch A; Gorbokon N; Lennartz M; Hube-Magg C; Fraune C; Bernreuther C; Lebok P; Clauditz TS; Jacobsen F; Sauter G; Uhlig R; Wilczak W; Steurer S; Minner S; Marx AH; Simon R; Burandt E; Krech T; Luebke AM
    Pathobiology; 2022; 89(4):245-258. PubMed ID: 35477165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer.
    Jeon Y; Jo U; Hong J; Gong G; Lee HJ
    BMC Cancer; 2022 Sep; 22(1):1014. PubMed ID: 36153494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target.
    Stepan LP; Trueblood ES; Hale K; Babcook J; Borges L; Sutherland CL
    J Histochem Cytochem; 2011 Jul; 59(7):701-10. PubMed ID: 21551320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB; Weaver R; Traina T; Dalenc F; Aftimos P; Lynce F; Diab S; Cortés J; O'Shaughnessy J; Diéras V; Ferrario C; Schmid P; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo MS; Itri LM; Rugo HS;
    N Engl J Med; 2021 Apr; 384(16):1529-1541. PubMed ID: 33882206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A literature review of the promising future of
    Wen Y; Ouyang D; Zou Q; Chen Q; Luo N; He H; Anwar M; Yi W
    Ann Transl Med; 2022 Dec; 10(24):1403. PubMed ID: 36660684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells.
    Zhang L; Yang G; Zhang R; Dong L; Chen H; Bo J; Xue W; Huang Y
    Int J Oncol; 2018 Aug; 53(2):515-526. PubMed ID: 29901071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
    Chou J; Trepka K; Sjöström M; Egusa EA; Chu CE; Zhu J; Chan E; Gibb EA; Badura ML; Contreras-Sanz A; Stohr BA; Meng MV; Pruthi RS; Lotan Y; Black PC; Porten SP; Koshkin VS; Friedlander TW; Feng FY
    Eur Urol Oncol; 2022 Dec; 5(6):714-718. PubMed ID: 35216942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon.
    Ahmed Y; Berenguer-Pina JJ; Mahgoub T
    Oncology; 2021; 99(10):673-680. PubMed ID: 34280931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
    Weiss J; Glode A; Messersmith WA; Diamond J
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
    [No Abstract]   [Full Text] [Related]  

  • 17. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG; Shah NC; Rugo HS; Goldenberg DM; Sweidan AM; Iannone R; Washkowitz S; Sharkey RM; Wegener WA; Kalinsky K
    N Engl J Med; 2019 Feb; 380(8):741-751. PubMed ID: 30786188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trop2: Jack of All Trades, Master of None.
    Lenárt S; Lenárt P; Šmarda J; Remšík J; Souček K; Beneš P
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33187148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-associated calcium signal transducer 2 regulates neovascularization of non-small-cell lung cancer via activating ERK1/2 signaling pathway.
    Guo X; Zhu X; Zhao L; Li X; Cheng D; Feng K
    Tumour Biol; 2017 Mar; 39(3):1010428317694324. PubMed ID: 28345466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
    Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
    Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.